×

RNS Number : 9380E

Concepta PLC

15 February 2018

 

15 February 2018

Concepta plc

("Concepta" or the "Company")

Concepta signs contract in China to support marketing of myLotus in Chinese hospitals

 

Concepta plc (AIM: CPT), the UK healthcare company and developer of a proprietary product targeted at the mobile health market with a primary focus on women's fertility, is pleased to announce that it has signed a marketing agreement with Wei Yi Bei Lian (Shanghai) Information Technology Co., Ltd ("BB Link").

BB Link offers free WiFi to waiting rooms in 1,500 maternity hospitals across China. Concepta has developed a landing page that will be displayed when patients connect to this WiFi service. The page will give an overview of the myLotus product and a link to the Concepta website where more in depth information can be found. Initially, Concepta's landing page will be launched in a select number of hospitals, and longer term, the Company will be able to reach hundreds of thousands of women in a phased rollout, through a highly targeted marketing channel.

Concepta's distributors will also train the doctors at these hospitals on the myLotus product, enabling them to provide further detailed information and recommendations to patients that could benefit from its use.

Erik Henau, CEO says: "Co-operation with BB Link allows us to target the most relevant potential users of myLotus in a cost-effective way. Additionally, if women are able to read about the product prior to seeing the doctor, there is a greater scope for market penetration.

"BB Link has developed a sophisticated platform with metrics that permit the measurement of campaign success. We will start with a trial that will help us to refine our key messages to our consumers and to learn how the information links to the logistics of the hospital route.

"This is an important step in building our consumer brand in China and in working with the hospital route to market."

Enquiries:

The Company

Erik Henau

CEO

Tel: +44 (0) 1234 866601

 

SPARK Advisory Partners Limited (Nomad)

Neil Baldwin / Mark Brady

Tel: +44 (0)20 368 355

 

NOVUM Securities Limited (Broker)

Colin Rowbury

+44 (0) 20 7399 9400

 

Yellow Jersey (Financial PR)

Georgia Colkin / Joe Burgess / Katie Bairsto

Tel: +44 (0) 776 932 5254

 

About Concepta Plc:

Concepta plc is an AIM-quoted pioneering UK healthcare company that has developed a proprietary product, myLotus, targeted at the personalised mobile health market with a primary focus on unexplained infertility* in women.

myLotus is currently the only consumer product which allows both quantitative and qualitative measurements of a woman's personal LH**and hCG***hormone levels in a home test, facilitating higher conception rates and early diagnosis of issues with fertility hormones. The proposition of myLotus is to help women conceive naturally.

Concepta has made significant progress recently, establishing agreements with a number of distributors in China where myLotus has been given cFDA approval. Concepta is initially targeting the traditional route to market in China through Chinese hospitals and plans to add the direct-to-consumer route in the near future.

The Company is also well on its way to achieving CE-marking and commencing its direct-to-consumer launch in the UK and Europe in H1 2018. The Company has identified a significant global market opportunity, with revenue potential of the Chinese and EU unexplained infertility market estimated to be worth c.£600m per annum.

*Unexplained infertility refers to women that have been unable to conceive after 6 months of trying. This highly motivated target group of consumers won't typically be offered medical intervention until 12 months of unsuccessfully trying, with IVF not offered until two years. Research indicates couples start to take positive action ahead of this time and there is little medical support to help them do so.

** LH: Luteinising hormone is produced by the pituitary gland and is one of the main hormones that control the reproductive system.

*** hCG: Human chorionic gonadotropin is a hormone produced by the placenta after implantation and is an indicator of pregnancy.

 

About RNS Reach announcements

RNS Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases such as marketing messages, corporate and product information into the public domain. An RNS Regulatory announcement is required to be notified under the AIM Rules for Companies.

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

NRALFFFFFEISLIT

Close

×

RNS Number : 5106E

YouGov PLC

12 February 2018

 

 

12 February 2018

YouGov plc

("YouGov" or "the Group")

 

New advertising platform YouGov Direct announced

YouGov Direct enables greater consumer data protection and effective ad targeting

YouGov, the international market research and data analytics group, today announces the development of a new digital advertising platform, YouGov Direct. Currently consumers have little control over their data, while ineffective targeting has a negative impact on brands and publishers. YouGov Direct aims to overcome those problems in the ad ecosystem by harnessing blockchain technology to verify the data exchange between consumers and advertisers.

Through YouGov Direct, panellists will be able to choose which personal attributes to make available to third parties while remaining anonymous. For example, a user might decide to share information about favourite hobbies and withhold data related to health history. In exchange for sharing their data, users will earn additional rewards.

Advertisers, brands and publishers using the platform gain access to known audience attributes, which enable more effective advertising targeting and better campaign performance. YouGov Direct's transparent and verifiable record of transactions provides assurance that ads are reaching actual humans as opposed to bots and will support businesses in meeting the requirements of the forthcoming EU General Data Protection Regulation (GDPR).

YouGov expects to launch the product to customers during the course of FY19.

To register your interest in YouGov Direct, go to direct.yougov.com.

 

Enquiries:

YouGov plc

Stephan Shakespeare / Alex McIntosh                  020 7012 6000

FTI Consulting (PR)

Charles Palmer / Harry Staight                                   020 3727 1000

Numis Securities (NOMAD and broker)

Nick Westlake / Toby Adcock                                     020 7260 1000

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

NRAUGUCWPUPRGMB

Close

×

RNS Number : 0957E

Malvern International PLC

07 February 2018

 

7 February 2018

MALVERN INTERNATIONAL PLC

("Malvern" or the "Company")

 

Launch of Malvern Online Academy

 

Malvern International plc (AIM: MLVN), provider of educational services in the UK, Europe and Asia, is pleased to announce the official launch of Malvern Online Academy ("MOA") which will provide online and live (real time) teaching and training sessions for existing and new students, including corporate trainees as well as members of the general public.  The sessions will be available in two formats:  real-time 'live' instructor-led sessions; and pre-recorded sessions which can be accessed at anytime.

 

MOA will aim to offer all courses and programmes currently being run in Malvern schools in London, Malaysia and Singapore.  The first programmes being offered through the online platform are the suite of English language courses currently taught in Malvern House London.  These will be available to students and schools in Asia, India, the Middle East, Europe and South America, all territories in which Malvern already has a market presence through educational institutions and agents.  Following on from the English classes, MOA's offering will be extended to include all its accounting and accountancy-related courses, with the ultimate aim of being able to offer all its existing courses including ones that are bespoke to suit the needs of various online customer groups.

 

Target markets will include alumni from all of Malvern's schools, as well as corporate entities and various organisations for which online professional development and training courses are well suited.

Commenting  Dr Sam Malafeh, Chief Executive Officer said " the global online market is expected to grow very significantly over the next decade. Building upon the creation of Malvern's digital learning and technology division in 2017, further development, innovation and expansion into the online market is a vital tenet of its strategic plan for 2018.  Malvern believes it is in an excellent position to capitalise strongly  on the current global demand for online learning by virtue of its existing span of high-quality programmes and offerings, the combined skills and expertise of its global teaching staff as well as its international network of partners, institutions and agents within the education industry."

For more information, please visit:

https://online.malverninternational.com 

Or: https://www.malverninternational.com/malvern-colleges/malvern-online-academy/

 

Contacts:
Malvern International plc	www.malverninternational.com
Haider Sithawalla Dr Sam Malafeh	+65 64120733 +65 83860155 / +447391035823
WH Ireland Limited	www.whirelandcb.com
Mike Coe, Ed Allsopp	+44 (0) 117 945 3470

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

MSCTFMATMBAMBPP

Close

×

RNS Number : 8042D

N4 Pharma PLC

02 February 2018

 

N4 Pharma Plc

("N4 Pharma" or the "Company")

Award of Grant

and

Collaboration with MedImmune UK

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company which reformulates existing drugs and vaccines to improve their performance, announces that it has been awarded a feasibility grant from Innovate UK, the UK's innovation agency, to co-fund a collaborative project with MedImmune UK, a leading global biologics R&D company, to explore the manufacture of a prototype nanomedicine using N4 Pharma's Nuvec® system.

 

The grant is from Innovate UK's Medicines Manufacturing Round 1: Challenge Fund, which itself is funded through the UK Government's £70m Industrial Strategy Challenge Fund to speed up the development of new medicines, details of which were announced on 22 January 2018 by Sam Gyimah, MP, the Universities and Science Minister. The project with MedImmune is expected to last for approximately nine months from 1 February 2018.

The grant is to enable N4 Pharma to develop manufacturing methods for Nuvec® particles loaded with therapeutic pDNA/mRNA encoding antigens and to demonstrate that such nanoparticles can be manufactured to the quality required for in-vivo studies. MedImmune will then evaluate these Nuvec formulations in relevant in-vitro and in-vivo models to demonstrate if they are able to deliver functional pDNA/mRNA capable of inducing an immune response.

Under the terms of the collaboration agreement with the Company, MedImmune has the right at any time during the collaboration project, and 3 months following its conclusion, to give notice that it wishes to negotiate the terms on which N4 would grant it an exclusive licence to utilise the results of the evaluation.

Further information on each of MedImmune UK and Innovate UK is set out below.

Nigel Theobald, CEO of N4 Pharma, commented: "We are delighted to have been awarded the feasibility grant from Innovate UK and to have the opportunity to work with MedImmune UK on this collaborative project. We continue to make great progress with our Nuvec® particles and we believe that MedImmune is the ideal partner to evaluate our nanoparticles in this field."

Enquiries:

N4 Pharma Plc Nigel Theobald, CEO	Via Alma PR
Stockdale Securities Tom Griffiths	Tel: +44(0)207 601 6100
Beaufort Securities Elliot Hance	Tel: +44(0)207 382 8300
Alma PR Josh Royston Robyn Fisher	Tel: +44(0)778 090 1979 Tel: +44(0)754 070 6191

 

About N4 Pharma

 

N4 Pharma is a specialist pharmaceutical company which reformulates existing drugs and vaccines to improve their performance.

N4 Pharma's reformulation work falls under two divisions:

• generic, already commercialised, drugs; and

• delivery of novel and existing vaccines.

N4 Pharma has identified a number of established drugs that could be improved upon through its reformulation techniques. N4 Pharma's most advanced reformulation is for sildenafil, widely marketed as Viagra, where N4 Pharma is seeking to improve the speed at which the drug takes effect whilst also extending its duration of action.

N4 Pharma's reformulation approach should take approximately three years to obtain regulatory approval as opposed to the traditional process for new drugs of on average ten years. The cost and risk profile of this model is also significantly less than the traditional process. N4 Pharma's business model for generics is to take reformulated drugs from its portfolio through to the stage where it will license its newly reformulated drugs to pharmaceutical companies to commercialise them. N4 Pharma's revenues should be derived from up front milestone and royalty payments associated with the licence.

N4 Pharma's business model for vaccines is to undertake the required clinical work to demonstrate the capability of its delivery system as a cancer vaccine or therapeutic treatment so that it can license the technology to major players developing treatments in this area, again in return for up front milestone and royalty payments associated with the licence.

 

About MedImmune UK

 

MedImmune is part of Astra Zeneca, having been acquired in 2007 for $15.6bn. It is a leading global biologics R&D company with one of the largest, most robust pipelines in the industry, including more than 120 research projects and product candidates, that comprise nearly half of AstraZeneca's overall R&D portfolio. It is focused on three core therapeutic areas: Oncology; Respiratory, Inflammation and Autoimmune; and Cardiovascular and Metabolic Disease. For further information visit:

https://www.medimmune.com/

 

About Innovate UK

 

Innovate UK is the UK's innovation agency. It works with people, companies and partner organisations to find and drive the science and technology innovations that will grow the UK economy. For further information on the recent announcment visit:

www.innovateuk.gov.uk

or

https://www.gov.uk/government/news/industrial-strategy-boost-for-uk-medicines-with-70-million-of-funding-to-help-develop-new-treatments

 

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

MSCSSSFDEFASESE

Close

×

RNS Number : 8305D

Gunsynd PLC

02 February 2018

 

Gunsynd plc

("Gunsynd", or the "Company")

Agreement with FastBase

Gunsynd Plc (AIM: GUN, NEX: GUN) is pleased to announce that it has entered into an agreement with Fastbase, Inc. ("FastBase"), a privately owned Danish SaaS (software as a service) company on the following terms:

In recognition of the efforts made by Gunsynd to assist FastBase in pursuing admission to trading on AIM, it is agreed that FastBase shall pay a consultancy fee of 0.75% of its market capitalization, subject to, and following completion of the IPO.  Such fee is to be paid and settled fully in new ordinary shares of the Company (issued as fully paid ordinary shares, at the Admission price).

About Fastbase, Inc. 

Built upon Google Analytics software, FastBase's software generates comprehensive lead reports that include extensive company profiles, visitor interaction, key employees with LinkedIn profile and email addresses. The insights provided by FastBase enable B2B businesses to contact their online leads in real-time.  

FastBase's popular web leads add-on to Google Analytics is now widely used, including by well-known brands.  It is targeting admission to AIM in Q2, 2018.

Hamish Harris, the Company's Executive Chairman, commented: "We are exceptionally pleased to be able to assist a rapidly growing SaaS company such as FastBase with its plans to list in London.  We will keep investors informed of progress with FastBase's progress in seeking admission to AIM."

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

 

The directors of Gunsynd accept responsibility for this announcement.

 

Contacts:-

 

Gunsynd plc:
Hamish Harris		+44 (0) 20 7440 0640
Nominated Adviser / NEX Exchange Corporate Adviser:
Cairn Financial Advisers LLP
James Caithie/Liam Murray		+44 (0) 20 7213 0880
Broker:
Peterhouse Corporate Finance
Lucy Williams		+44 (0) 20 7469 0930

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

AGRLLFIRFLIFIIT

Close

×

RNS Number : 2706D

Pennant International Group PLC

30 January 2018

 

 

 

30 January 2018                                   

 

 

Pennant International Group plc: 

CELEBRATING 60 YEARS OF GROWTH AND INNOVATION

1958 – 2018

 

Pennant International Group plc ("Pennant" or the "Group"), the AIM quoted supplier of integrated training and support solutions, products and services, principally to the defence, rail, aerospace and naval sectors and to Government Departments, will be 60 years old on 25 February, 2018.

 

Over the past six decades it has evolved, from modest beginnings, into a market-leading technology-led business with a truly global customer base. It has come a long way since its founder, John Williams commenced developing animated displays using a patented light system, the forerunners of today's sophisticated software training systems. Following on from these beginnings, capabilities were extended to include the manufacture of specially designed scaled models, where early projects included collaboration with Sir Christopher Cockerell to produce prototype designs of the world's first Hovercraft. In 1965, Brian Crawford and David Henderson joined the Company and introduced new technology which opened up the markets of education and training.

 

This resulted in substantial growth for the business, with increased demand for procedural and maintenance trainers for civil and military equipment. The Company continued to expand its technical capabilities, embracing technological advances by taking on larger programmes and producing ever more sophisticated training aids as well as expanding its product offerings still further to include Omega PS LSAR software.

 

The Company's flotation on the London Stock Exchange in March 1998 not only provided much easier access to capital to finance further growth but also a considerably greater public profile which in turn helped to open the doors to a number of  government, defence and international markets and facilitate further significant expansion.

 

Today, the Group is recognised as one of the world's leading suppliers of integrated training and support systems, products and services.

 

Commenting on this major milestone for Pennant and also looking ahead to its continued growth and development, Phil Walker, Group CEO, said:

"I'm proud to be a part of a Company with such a rich heritage and one which has very much moved with the times. Any business is only as good as its people, and I would like to take this opportunity to thank employees past and present for their skills, support and dedication and for making Pennant what it is today, an internationally acknowledged leader in its chosen markets.

 

"Looking to the future, I believe the business is well placed to deliver further growth and innovation, continuing to develop new products and services as we enter the next phase in Pennant's long and distinguished history."   

 

 

 

Enquiries:

 

Pennant International Group plc	www.pennantplc.co.uk
Philip Walker, CEO David Clements, Commercial Director	+44 (0) 1452 714 914 +44 (0) 1452 714 914
WH Ireland Limited	www.whirelandplc.com
Mike Coe / Ed Allsopp	+44 (0) 117 945 3470
Walbrook PR (Financial PR)	[email protected]
Paul Vann / Tom Cooper	+44 (0)20 7933 8780 Mob: +44 (0)7768 807631

     

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

NRAGMGZMFLMGRZZ

Close

×

RNS Number : 8187C

Character Group PLC

24 January 2018

 

 

 

 

 

THE CHARACTER GROUP PLC

 ("Character", "Group" or "Company")

 

Designers, developers and international distributor of toys, games and giftware

 

Two Toy of the Year Awards for Character

 

London: Wednesday 24 January 2018: The Character Group plc (AIM: CCT) is delighted to announce that its principal trading subsidiary, Character Options Limited ("Character Options"), is celebrating not one, but two, successes at the annual Toy Industry Awards held last night (Tuesday 23 January 2018) at The London Toy Fair.

 

Each year the Toy Retailers Association comes together to announce which toys were most successful in the previous 12 months, with several awards being granted within their own categories.  Character Options was announced the winner of two: Best Electronic Toy for the Laser X Dual Pack, manufactured by NSI International Inc., and Best Action Toy for The Original Stretch Armstrong manufactured under licence from Hasbro.  Each of these toys were also awarded the status of Dream Toys in November 2017.  http://www.rns-pdf.londonstockexchange.com/rns/8187C_-2018-1-24.pdf

Jerry Healy, Group Marketing Director, said;

"The Toy Industry Awards night is a very important occasion as it gives credit to the 'best in class' toys of the previous year.  Everyone at Character is therefore delighted to once again be awarded two of these important accolades." 

Jon Diver, Joint MD at Character, added;

"The success also signifies the prospects for the year ahead of these two brands.  Laser X was successful from the moment it launched last July and, this year we will be extending the brand with two further toy lines, the Laser X Battling Tower and the Laser X Long Range Blaster.  Stretch Armstrong has now developed into a full product range of characters, including iconic figures from the past, Vac Man and the Stretch Monster and is one of Characters' fastest growing brands."

Kiran Shah, Joint MD at Character, also commented:

 

"The London Toy Fair this week is proving to be another great expo for us -we are currently exhibiting our full range of 2018 products and the feedback we are receiving from customers and trade visitors to the London Toy Fair is very encouraging.  We are confident that the performance of our core ranges and these new introductions will result in further growth in demand for our products, in the calendar year ahead."

 

 

ENQUIRIES:

The Character Group plc Jon Diver, Joint Managing Director Kiran Shah, Joint Managing Director & Group Finance Director Jerry Healy, Group Marketing Director

 

Office:      +44 (0) 208 329 3377 Mobile:    +44 (0) 7956 278522 (KS) Mobile:    +44 (0) 7831 802219 (JD) Email:  [email protected]

 

FTSE sector:  leisure: FTSE AIM All-share: symbol: CCT.L Market cap: £96m Copies of this statement can also be viewed at www.thecharacter.com  Product ranges can be viewed at www.character-online.co.uk  Email: [email protected]
Panmure Gordon (Nominated Adviser and Joint Broker) Andrew Godber, Investment Banking Tom Salvesen, Corporate Broking Tel:  +44 (0) 20 7886 2500
Allenby Capital Limited (Joint Broker) Nick Athanas Katrina Perez Tel:  +44 (0) 20 3328 5656
TooleyStreet Communications Limited (Investor and media relations) Fiona Tooley Tel:  +44 (0) 7785 703523 Email: [email protected]
Evolution PR (Trade Press enquiries) Michele Bates, Managing Director Tel: +44 (0)1327 227010 Mobile: +44 (0) 7725 616059 Email: [email protected]

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

NRABIMJTMBJTBBP

Close

×

RNS Number : 4523C

APC Technology Group PLC

22 January 2018

 

22 January 2018

 

 

APC Technology Group PLC

 ("APC" or the "Company")

 

APC to distribute 3D PLUS space components in UK

 

APC Technology Group PLC (AIM: APC), the design, specification and distributor of specialist technologies and electronic components, has signed an agreement to become the UK and Ireland distributor for 3D PLUS, a world leading manufacturer of advanced high density 3D microelectronics products for space applications.

 

3D PLUS, a Heico Company (NYSE: HEI), has an impressive 18 year' heritage within the space sector, achieving preferred supplier status for the European Space Agency and sending more than 125,000 modules into space.

 

APC's high reliability component division, APC Hi-Rel, has significant experience in designing in components into space programmes including ExoMars, BepiColombo and EarthCARE. The addition of 3D PLUS products enhances APC's range of space-qualified peripheral products such as DC-DC converters, optocouplers, crystal oscillators, capacitors, diodes and connectors – to now include 3D PLUS memory, interface and point of load converter products.

 

Patrice Benard of 3D Plus, said:

 

"APC Hi-Rel has a long history of working with organisations within the space, defence and medical sectors, which perfectly compliments our extensive product range. Their technical and engineering expertise, and strong reputation within the industry, will be an asset to designing in 3D PLUS products to bring breakthrough advantages to customers' electronic designs".

 

Richard Hodgson, CEO of APC Technology Group, commented:

 

"The combination of our existing space technologies, the premier space products that 3D PLUS bring, our prestigious customers and APC's experienced and knowledgeable team, gives us a great base for expansion in this exciting market.

 

As we set out in our results presentation, we are concentrating on three main growth drivers: growth through increased bookings from our existing technologies, in particular those that sit in high growth markets; growth through the signing of new complementary product lines; and growth through targeted bolt-on acquisitions. We have just announced our first bolt on acquisition and the signing of 3D PLUS demonstrates real traction in the signing of new technologies."

 

 More information on the 3D PLUS range of space products visit: http://apcplc.com/news-posts/apc-hi-rel-broadens-components-range-space-applications/

 

 

Enquiries:

 

APC Technology Group PLC                                                                               +44 (0) 330 313 3220

Richard Hodgson, Chief Executive                                                                   www.apcplc.com

Michael Thompson, Finance Director                           

                                                                                                                            

Stockdale Securities Limited (Nominated Adviser and Broker)                +44 (0)20 7601 6100

Mark Brown / Antonio Bossi / Edward Thomas

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

NRABRGDBBXBBGIC

Close

×

RNS Number : 3676C

Cronin Group PLC

19 January 2018

 

19 January 2018

Cronin Group Plc

("Cronin Group")

Publication of Scientific Paper

Publication in international weekly science journal, Science, of digitization of multi-step organic synthesis

 

Cronin Group, the AIM listed company focusing on digitizing chemistry, announces that its scientific founder and Non-Executive director, Professor Lee Cronin, has published in Science, the international weekly science journal, a paper demonstrating the digitization of chemistry for synthesis on demand.

 

The manufacture of active pharmaceutical ingredients ("APIs") is vital for modern healthcare, yet critical drugs are regularly manufactured for a finite period in a limited number of sites. To alleviate this issue, Professor Cronin proposes a concept whereby the large-scale manufacturing process of complex fine chemicals, such as APIs, is augmented by distributed, point-of-use manufacturing in self-contained cartridges requiring limited user interaction to produce the desired products on demand. 

 

Using some 3D printing methodologies covered in Cronin Group's patent US9643152, "Apparatus and methods for the preparation of reaction vessels", the authors demonstrated the translation of benchscale synthesis procedures into a step-by-step workflow that could be used to create digital designs for custom reactionware that can be fabricated by using three-dimensional (3D) printing technologies.

 

Professor Lee Cronin, Non-Executive director of Cronin Group, commented: "I'm very excited about the different market opportunities which the digitization of chemistry has the potential to open up."

 

The full manuscript of "Digitization of multi-step organic synthesis in reactionware for on-demand pharmaceuticals" can be found at http://science.sciencemag.org/content/359/6373/314.

 

 

For further information:

 

Cronin Group Plc	www.croningroupplc.com
Mark Warne, Executive Chairman	T:  0141 465 6871
Stockdale Securities Limited	T: 020 7601 6100
Tom Griffiths/Edward Thomas

 

 

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

NRAKMGMMRLMGRZG

Close

×

RNS Number : 9367B

Genedrive PLC

16 January 2018

 

For release: 16 January 2018

 

genedrive plc ("genedrive" or the "Company")

 

First Successful Field Evaluation of Genedrive® HCV Assay in Africa

 

Performance Study in Johannesburg Demonstrated 100% Sensitivity and Specificity

 

genedrive plc, (AIM: GDR), the near patient molecular diagnostics company, today announces successful results of the first field study of its Genedrive® Hetaptitis C (HCV) ID Kit in Africa.

 

The study, performed in Johannesburg at Lancet Laboratories, one of the leading private pathology testing laboratories operating throughout Africa, was designed to verify genedrive HCV's assay performace across the diverse genotypes which are prevalent in Africa compared to Europe.  

 

In a cohort of 130 clinical samples from South Africa, Kenya, Ghana, Nigeria, Uganda, and other Sub-Saharan countries, the Genedrive® HCV ID Kit demonstrated sensitivity and specificity of 100% compared to the Abbott M2000 HCV Real time assay as a reference.  The cohort was composed mostly of HCV genotypes 1a, 4, and 1b, with the remaining 16% samples from genotypes 2, 3, and 5.  The test also demonstrated efficiency of 95.4% (result achieved first attempt).

 

"These positive results with the genedrive HCV assay in customer hands on local samples confirms that our good clinical validation performance can be translated into real-world settings where the test will be used, " said David Budd, Chief Executive Officer of genedrive plc. "Our test is the first to market as a decentralised qualitative molecular HCV test for use at the point of need.  We remain confident it can play an important role in the diagnosis and management of the disease in Africa and in other territories where access to centralized laboratories is limited."  

 

Dr Allison Glass, Pathologist-in-Charge at Lancet Laboratories Johannesburg, commented, "Our trained laboratory staff found the Genedrive® HCV system and kit easy to operate, and, compared to the Abbott M2000 platform, required no maintenance, had a small laboratory foot print and faster processing time. Many of the original samples were haemolysed but produced valid results first time, demonstrating the robustness of using PCR direct from plasma. The genedrive HCV kit has the potential to decentralise clinical management of chronic HCV, which may result in the expansion of treatment programmes to rural areas of resource-limited countries."

 

The study follows the recent announcement that genedrive plc has signed a distribution agreement with Sysmex Europe GmbH, a subsidiary of Sysmex Corporation, a world leader in clinical laboratory systemization and solutions, for the Genedrive® HCV ID Kit and Genedrive® platform in the EMEA region with an initial focus on Africa. genedrive plc also entered into a distribution agreement with Sysmex Asia Pacific Pte Ltd, a subsidiary of Sysmex Corporation, for its CE-marked Genedrive® HCV ID Kit and Genedrive® platform in the Asia Pacific region.

 

 

–  Ends  –

 

For further details please contact:

genedrive plc

David Budd: CEO                                                                                                              +44 (0)161 989 0245

Matthew Fowler: CFO

 

Sysmex Europe GmbH

Fernando Andreu: Senior Executive Officer                                                                +49 40 527 260

Jens Behrens: Director, Marketing Communications

 

Peel Hunt LLP

James Steel                                                                                                                       +44 (0)207 418 8900

Oliver Jackson

 

Consilium Strategic Communications

Chris Gardner                                                                                                                    +44 (0)203 709 5700

Matthew Neal

Laura Thornton

[email protected] 

 

 

Notes to Editors

 

About genedrive plc

genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Genedrive® HCV ID Kit has recived CE marking. Further details can be found at: www.genedriveplc.com and www.genedrive.com 

 

About Sysmex Europe

Sysmex Europe GmbH (SEG), located near Hamburg, Germany, is a subsidiary of the Sysmex Corporation from Kobe, Japan. From our Hamburg offices – designated a Great Place to Work® in 2014 and 2016 – we serve our affiliates, distributors and customers throughout EMEA – Europe, the Middle East and Africa. Globally we employ around 8000 staff, of whom 1300 work in the EMEA region.

Sysmex is the global leader in haematology and a renowned specialist in haemostasis, urinalysis, and laboratory automation. As our expertise in the interdependency of disease and medical disciplines grows, we are growing to cover other pressing areas such as oncology, flow cytometry, liquid biopsy and essential healthcare in resource-poor regions. This is allowing us to deliver clinical value that primary healthcare workers such as physicians, surgeons and other specialists can use directly to deliver better diagnostics, treatment and monitoring, and so improve the quality of life of their patients. Everything we do is driven by a single mission: Shaping the advancement of healthcare. For more information about Sysmex Europe, please visit www.sysmex-europe.com, and for details on Sysmex Africa www.sysmex.co.za

 

About Hepatitis C

Hepatitis C is an international public health challenge, comparable to other major communicable diseases, including HIV, tuberculosis and malaria. It is estimated that 150-200 million people, or approximately 3% of the world's population, are living with chronic hepatitis C, and more than 350,000 people die yearly from hepatitis C related diseases. In 2016, WHO published the first global health sector strategy on Hepatitis with a goal of eliminating viral hepatitis as a major public health threat by 2030. New oral, well-tolerated treatment regimens can achieve cure rates of over 90% however access to rapid, inexpensive and accurate diagnostics are a critical bottleneck that must be addressed to eradicate Hepatitis C.

 

 

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

NRAEAXFSFAXPEFF

Close